Concord Biotech Enters $30 Mn U.S. Opportunity

Concord Biotech jumps after receiving USFDA approval for Mycophenolate Mofetil Oral Suspension — a key immunosuppressant used in kidney, heart, and liver transplant patients. The approval gives the company entry into a US$30 million U.S. market, further strengthening its global pharma portfolio and long-term international growth strategy. Technically, the stock has also witnessed a strong breakout on the weekly chart with sharp volume expansion, indicating renewed buying interest.